Exploratory analysis of front-line therapies in REVEL: a randomised phase 3 study of ramucirumab plus docetaxel versus docetaxel for the treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy - Garon, Edward B.; Scagliotti, Giorgio Vittorio; Gautschi, Oliver; Reck, Martin; Thomas, Michael; Docampo, Lara Iglesias; Kalofonos, Haralabos; Kim, Joo-Hang; Gans, Steven; Brustugun, Odd Terje; Orlov, Sergey V.; Carter, Gebra Cuyun; et al. (ESMO open, 2020)
Gesehen am 18.05.2020